AI-based MRI and ultrasound for thyroid-related eye disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multicenter observational study that prospectively validates an AI multimodal model built from orbital MRI sequences and ocular ultrasound for TAO. The study compares AI-driven assessments of presence, activity, severity, and prognosis between TAO patients and controls. Participants undergo standardized MRI scans including multiple sequences and receive ocular ultrasound, with data collected in real-world clinical settings. The goal is to determine how accurately the AI model can classify TAO status and forecast disease trajectory. Real-world applicability and diagnostic performance across diverse patients are central to the approach.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* TAO patient group

  * Age between 18 and 75 years old, regardless of gender.

    * Patients with thyroid eye disease who meet the disease staging and grading criteria specified in diagnostic guidelines such as those of Bartley, CAS, and EUGOGO.

      * The patient has planned or received thyroid-related treatment, and the condition is relatively stable.

        * Voluntarily participate in this study and sign the informed consent form.

Control group:

① Healthy volunteers matched with the TAO group in terms of age and gender.

② Voluntarily participate in this study and sign the informed consent form.

Exclusion Criteria:

* TAO patient group:

  * Pregnant or lactating women.

    * Patients with other orbital lesions.

      ③ Having contraindications for MRI examination (such as non - compatible metal implants in the body, claustrophobia, etc.).

      ④ The patient has previously received orbital radiotherapy or orbital surgery (except for patients who need to collect tissue specimens).

      ⑤ Comorbid with other severe systemic diseases (such as uncontrolled heart failure, liver and kidney failure) or mental illnesses, and unable to cooperate to complete the study.

      ⑥ Participated in other clinical trials that may interfere with the results of this study within 3 months.

Control group:

Same as the exclusion criteria 1 - 6 for the TAO patient group

Where it's running

• Shanghai Changzheng Hospital
  Shanghai, Huangpu District, China Recruiting

Study contacts

• Study coordinator: Tuo Li, Vice Professor
• Email: zoe_leeto@hotmail.com
• Phone: +86-13918507887

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ETHY-001 safety and activity in Thyroid Eye Disease (TED)

  This study tests ETHY-001 versus placebo to see if it is safe, tolerable, and shows activity in people with thyroid eye disease.

  Recruiting at 2 sites Phase 1 Ethyreal Bio, Inc. · Orland Park, Illinois and 2 other locations · NCT07885605

• Efgartigimod for Graves' Disease in adults

  We are testing if efgartigimod given under the skin can help adults with Graves' disease by improving thyroid function and whether it is safe and tolerable.

  Recruiting at 35 sites Phase 3 argenx · Carlsbad, California and 34 other locations · NCT07570316

• Links between inflammation, thyroid antibodies, and retinal changes in Graves disease

  This study will see if blood markers of inflammation and thyroid antibodies are linked to retinal measurements from OCT in adults with Graves disease and in healthy adults.

  Recruiting Elazıg Fethi Sekin Sehir Hastanesi · Elâzığ, Elaziğ · NCT07480720

• Teprotumumab for treating thyroid eye disease and thyroid dysfunction

  This study is testing how well teprotumumab can help people with thyroid eye disease who have serious symptoms like bulging eyes, pain, and double vision.

  Recruiting Walter Reed National Military Medical Center · Bethesda, Maryland · NCT06275373

• Early risk stratification of thyroid eye disease in newly diagnosed Graves' disease

  This study tests whether early eye-related signs, blood and tear biomarkers, or eye surface features can predict who with Graves’ disease will develop thyroid eye disease within a year.

  Recruiting University of Copenhagen · Herlev · NCT07812194

• Felzartamab for Graves’ Disease: See if it helps control thyroids and reduce need for ATDs

  This study tests felzartamab vs placebo in adults with Graves’ disease to see if it can normalize thyroid hormones and let people stop anti-thyroid drugs.

  Recruiting at 14 sites Phase 2 Biogen · Glendale, Arizona and 13 other locations · NCT07722546

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.